African sleeping sickness is endemic to vast areas of subSaharan Africa. The World Health Organization estimates that 55 million people in 35 African countries are at risk for contracting the disease, which is invariably fatal to untreated individuals (29) . An alarming resurgence of African sleeping sickness in Sudan and other parts of Central Africa has created great concern among African governments and international health care agencies. Pentamidine and the organoarsenicals (e.g., melarsoprol and melarsen), which have been used to treat African sleeping sickness for many years, are highly toxic and have led to drug-resistant clinical strains that are refractory to chemotherapy (9, 29) . The drug ␣-difluoromethylornithine (ornidyl, eflornithine), which was approved by the FDA in 1990 for treatment of the disease, is costly to prepare, cumbersome to administer, and ineffective against the disease forms prevalent in East Africa (29) . At present, DB289, a prodrug of the pentamidine analog 2,5-bis(4-amidinophenyl)furan, is the only potential new treatment undergoing clinical trials for earlystage human African sleeping sickness (41) . New agents for the treatment of African sleeping sickness are urgently needed (9, 14, 29) . Ideally, these should be highly effective in eradicating host-dwelling parasites, nontoxic to the host, inexpensive to produce, and easy to administer to patients in rudimentary medical care settings.
Polyamine biosynthetic pathways in trypanosomes have provided effective targets for the development of trypanocidal agents (4) . Difluoromethylornithine, the agent used to treat late-stage African sleeping sickness, is an inhibitor of ornithine decarboxylase (5, 6) . Another polyamine pathway enzyme, 5Ј-deoxy-5Ј-(methylthio)-adenosine phosphorylase (MTA-Pase), has been studied by our laboratories as a potential trypanocidal target. 5Ј-Deoxy-5Ј-(methylthio)-adenosine MTA, the nucleoside by-product of spermidine synthesis in trypanosomes, is cleaved by MTA-Pase to generate methylthioribose-1-phosphate (MTRP) and adenine ( Fig. 1) . MTRP is recycled to methionine, while adenine is redirected to nucleoside synthesis. Trypanosomes lack de novo purine biosynthetic pathways (11) . In addition, they have continuously high demands for S-adenosylmethionine (AdoMet), the methionine metabolite that serves as a polyamine precursor (22) . MTA-Pase plays a critical role in these parasites by enabling the salvage of adenine and methionine, both of which are essential for trypanosome survival (11, 22) . Moreover, MTA-Pase presents a selective chemotherapeutic target in African trypanosomes, based on a significant difference in the substrate activities of the MTA analog, 5Ј-(hydroxyethylthio)-adenosine (HETA), toward mammalian and trypanosome forms of MTA-Pase: the trypanososme form of MTA-Pase (Tryp-MTA-Pase) rapidly metabolizes HETA, whereas the mammalian enzyme is comparably ineffective (8, 44) . Although the mechanism of HETA's toxicity is not known, its rapid breakdown, once it is inside trypanosomes, is an indication that these effects are not caused by the inhibition of Tryp-MTA-Pase. More likely, HETA's toxicity is related to its ability to interfere with methionine recycling. This is supported by the finding that HETA's in vitro trypanocidal effects can be reversed by the concomitant administration of methionine or 2-keto-4-methylthio-butyrate, the immediate precursor of methionine salvage from MTA (8). HETA's toxicity may also be associated, in part, with the generation of a toxic methionine analog, as was observed in Klebsiella pneumonia (32) . Other key biochemical properties that contribute to HETA's trypanocidal potency include its rapid, carrier-mediated accumulation inside trypanosomes via the P2 purine transporter and a novel AdoMet transporter discovered in these parasites (19, 20, 22) . HETA was observed to induce elevations in AdoMet and MTA levels in trypanosomes (3) and to inhibit trypanosome protein methylation reactions (21) . The preferential metabolism of HETA by MTA-Pase in trypanosomes, which provided the initial basis for its potential selectivity, was supported by results from in vivo studies demonstrating its curative effects in mice infected with Trypanosoma brucei brucei and T. brucei rhodesiense strains and the absence of host toxicity (7, 8) . These in vivo studies strongly validated the designation of HETA as a lead compound for further analog development. Our continuing efforts to identify more potent structural analogs of our lead compound, described in this study, have centered on the synthesis and in vitro antitrypanosomal screening of novel purine-and ribose-modified analogs of HETA. 
MATERIALS AND METHODS
MTA analogs. The structures of the MTA analogs that were evaluated for trypanocidal activity in this study, as well as in previous studies (3, 8, 43) , are depicted in Tables 1 to 4 . The structures of the 13 newly synthesized analogs are highlighted by boldface type in all tables; the methods developed for their chemical synthesis appear in the supplemental material (1, 10, 23, 25, 31, 33, 34, 35, 37, 47) . Also included in the supplemental material are detailed methods for the synthesis of 2-amino-HETA, 2-fluoro-HETA, and 2Ј-deoxy-HETA, analogs whose trypanocidal effects were reported previously (3, 43) . Confirmation of the structures of the newly synthesized analogs was accomplished by KETRI 243 is resistant to pentamidine and melarsoprol, and KETRI 269 is resistant to pentamidine (2) . KETRI 243-As10-3 is a highly melarsen-and diamidine-resistant clone of KETRI 243 (2). The bloodstream forms of the strains were adapted to grow under axenic conditions in Iscove's modified Dulbecco medium with hypoxanthine at 1 M and 20% horse serum instead of synthetic serum (HMI-18 medium) (24) .
MTA phosphorylase enzyme assays. Cell-free enzyme preparations were obtained from bloodstream trypanosomes by a previously published procedure (8). 
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Briefly, bloodstream trypanosomes were harvested from rats. Cell lysates were frozen-thawed in dry ice-methanol for three cycles and centrifuged at 5,000 ϫ g for 10 min, and endogenous unbound phosphate was removed by dialysis for 1 h (0.05 M Tris-HCl, 0.1 mM disodium EDTA, 1 mM 2-mercaptoethanol, pH 7.4). Trypanosome extracts were frozen and stored at Ϫ70°C. MTA analogs were assayed for their ability to act as substrates for Tryp-MTA-Pase with and without added phosphate in the reaction mixture. Enzyme assays were based upon the phosphorolysis of MTA to yield adenine. The conversion of adenine to 2,8-dihydroxyadenine in the presence of commercial xanthine oxidase was measured at 305 nm (change in E ϭ 15.5 ϫ 10 3 M Ϫ1 cm Ϫ1 ). The reaction mixtures (1-ml final volume in quartz cuvettes) contained 0 or 50 mM potassium phosphate (pH 7.4), xanthine oxidase (1,000 U; type III; Sigma Chemical Co., St. Louis, MO), and 100 l of trypanosomal extract. MTA or its substrate analog (25 to 500 M) was added to start the reaction. Normally, 200 M MTA or its analog was saturating. The increase in absorbance over 1 h was measured in a recording spectrophotometer (DU7; Beckman) with a temperature-controlled cuvette holder (37°C). The rates were linear for the 1-h period (18) .
Determination of in vitro antitrypanosomal activity. Drug studies were done in duplicate in 24-well plates (1 ml per well) with final inhibitor concentrations of 0.1, 1, 10, 25, and 100 M. After 48 h, the number of parasites was determined in a Z1 Coulter counter, and the approximate range of activity was determined. The 50% inhibitory concentrations (IC 50 s) were then determined from additional studies with a narrower range of inhibitor concentrations. Inhibitors with Ͻ50% inhibition at 100 M were considered inactive and their IC 50 values were not further determined. Analogs were dissolved in water or dimethyl sulfoxide. Dilutions were made with HMI-18 medium, such that the dimethyl sulfoxide concentration never exceeded a noninhibitory concentration of 0.3%.
RESULTS
MTA phosphorylase assays. MTA analogs, whose structures are depicted in Tables 1 to 4 , were assayed for their abilities to act as substrates for Tryp-MTA-Pase with and without phosphate added to the reaction mixture. Inorganic phosphate is an absolute requirement for MPA-Pase activity. Thus, the MTA substrate analogs display differential activities in the presence and absence of phosphate: MTA substrate activity is 20.86 nmol/mg protein/h with added phosphate, and with no added phosphate, the baseline activity is 7.67 nmol/mg protein/h, likely contributed by the action of nonspecific nucleosidases ( Table 5 ). As seen in (Table 6 ). These compounds were grouped according to their relative activities: the highly active analogs (those active at concentrations of Յ1 M), which consisted of HETA (compound Ib), HETT (compound IIIa), and MFETA (compound VIIc); active analogs (analogs active at concentrations of 2 to 10 M), which consisted of 2-amino-HETA (compound IIa), 2-fluoro-HETA (compound IIb), and 8-aza-HETA (compound IV); moderately active analogs (analogs active at concentrations of 10 to 50 M), which consisted of HET-MPR (compound Id), 5Ј-deoxy-5Ј-(hydroxyethylthio)-nebularine (HETN; compound Ie), 3Ј-deoxy-HETA (compound IXb), and 2Ј,3Ј-seco-HETA (compound X); active analogs (analogs active at concentrations of 50 to 100 M), which consisted of MTT (compound IIIb); and inactive analogs (analogs active at concentrations of Ͼ100 M). Most analogs were either slightly growth inhibitory or non-growth inhibitory for T. brucei brucei LAB 110 EATRO. Unexpectedly, three analogs, 5Ј-deoxy-5Ј-(hydroxyethylthio)-ribavirin (HET-RV; compound V), AETA (compound VIIh), and 2Ј-deoxy-HETA (compound IXa), were observed to stimulate the growth of a drug-resistant strain (KETRI 243 or 243-As10-3).
DISCUSSION
The biochemical differences between the mammalian and the microbial pathways of MTA metabolism as selective targets for drug design have been studied extensively (3, 4, 7, 8, 18, 28, 36, 40, 42) . Unlike mammalian cells, two distinct pathways of MTA metabolism are known to exist among microbial species ( Fig. 1 We identified one such MTA analog, HETA, and found, as anticipated, that HETA has significantly greater cytotoxicity for trypanosomes than for mammalian cells (8) .
In seeking to enhance HETA's trypanocidal activity, we synthesized new analogs which were assayed for their susceptibility to cleavage by Tryp-MTA-Pase and for their in vitro trypanocidal activity in T. brucei brucei LAB 110 EATRO and at least one drug-resistant KETRI clinical isolate. The biological results from the present study were compared with relevant data from previous studies (3, 8, 43) in order to determine the distinct effects of each structural modification on enzyme activity and trypanocidal activity, respectively (Tables 5 and 6 ). The most significant increase in substrate activity occurred when an exocyclic fluoro substituent was added at the C-2 position of the purine moiety, as evidenced by the substrate activity of 2-fluoro-HETA (compound IIb), which was 1.5 times greater than that of MTA and HETA. The greatest enhancement in trypanocidal activity resulted from replacement of the N-7 nitrogen of HETA by a C atom; thus, when HETT (IC 50 value, 10 nM) was evaluated with pentamidineresistant clinical isolate KETRI 269, it was 45 times more potent than HETA (IC 50 value, 450 nM).
MTA-Pases from mammalian and microbial sources are known to have a broad tolerance for substrates with various alkyl and aryl substituents as replacements for the terminal 5Ј-methyl group (3, 8, 12, 15, 18, 28, 44) . Accordingly, a library of novel S-alkyl and/or S-aryl analogs of MTA is likely to contain a small subset of MTA analogs that are more susceptible to cleavage by microbial MTA-Pases than by mammalian MTA-Pases. Our initial success in identifying HETA as one such MTA analog was further validated by a detailed comparison of the mammalian and trypanosome MTA-Pase substrate activities of a selected group of S-alkyl-modified MTA analogs. The Tryp-MTA-Pase substrates had decreasing activity in the following order:
The mammalian-MTA-Pase substrates have decreasing activity in the following order (44): MTA (100%) ϭ PTA Х ETA Ͼ MFPTA (64%) ϭ MFETA Ͼ HETA (34%). The noteworthy increase in the Tryp-MTA-Pase substrate activity of HETA compared with that of ETA and the increase in the Tryp-MTA-Pase substrate activity of HPTA compared with that of PTA are a consequence of the addition of a terminal hydroxyl group. By contrast, the addition of a hydroxyl group reduces the substrate activity toward mammalian MTA-Pase by 60% (i.e., for HETA compared with that of ETA).
Our initial in vitro studies of HETA and MFETA pointed to a direct association between their trypanocidal effects and their efficacies as substrates of Tryp-MTA-Pase and implied that their cytotoxicity is mediated through interference with methionine recycling (8) . This is supported by the finding that HETA's in vitro trypanocidal effects can be reversed by the concomitant administration of methionine or 2-keto-4-methylthio-butyrate, the immediate precursor of methionine salvage from MTA (8) . However, the current studies, which encompass a more extensive series of purine-and ribose-modified MTA analogs, do not substantiate the link between substrate activities and IC 50 values for many compounds. We have shown that VOL. 52, 2008 NOVEL TRYPANOCIDAL ANALOGS OF 5Ј-METHYLTHIOADENOSINE 215 HETA has many effects on the metabolism of African trypanosomes. These include increases in AdoMet, S-adenosylhomocysteine, and MTA concentrations to unphysiological levels; decreases in spermidine concentrations; and a reduction of the level of methylation of proteins (3). HETA's trypanocidal effects are enhanced by its extremely rapid uptake and concentration by parasites, with its concentration reaching Ͼ800 M in minutes (3). This suggests that additional factors, such as differences in carrier-mediated transport and the involvement of other biochemical targets, also contribute to the trypanocidal effects of HETA and its analogs. To overcome possible barriers to the active transport of these novel HETA analogs, we prepared, as potential prodrugs, their O-acetylated derivatives, which are expected to readily diffuse across the outer membrane. In fact, O acetylation of several analogs, HET-MPR, HETN, HET-RV, etheno-HETA, 2Ј,3Ј-deoxy-HETA, and 3Ј-deoxy-HETA, markedly enhanced their IC 50 values (Table 6 ). Enzyme and growth inhibition assays have been used throughout our studies as preliminary screens to select compounds as possible candidates for in vivo evaluations. In seeking compounds with IC 50 values Յ1 M, we identified HETA, MFETA, and 2-fluoro-HETA in prior studies (3, 8) ; and in the present studies, we identified HETT, tri-O-acetyl-HETT, and di-O-acetyl-3Ј-deoxy-HETA. HETT, the most cytotoxic compound that we have identified in our in vitro screening assays, is neither a substrate nor an inhibitor of Tryp-MTA-Pase. Table 5 indicates that while HETT is not an inhibitor of Tryp-MTA-Pase, it inhibits the nonphosphorolytic cleavage of MTA and, presumably, other nucleosides. Note the difference in enzyme activity without PO 4 Ϫ in the presence of MTA alone and in the presence of MTA and HETT in Table 5 . Since trypanosomes and related kinetoplastid protozoa have extensive purine and purine nucleoside salvage pathways, this finding suggests that some nucleoside analogs which are not cleavable by MTA-Pase may be converted to nucleotides by a nonspecific nucleoside phosphotransferase, such as that which happens with allopurinol in the T. brucei brucei group (17). Taken together, these observations indicate that the potent trypanocidal effects of HETT and 3Ј-deoxy-HETA are elicited by their interactions with a novel, unidentified molecular target(s). Since neither analog is a substrate of Tryp-MTA-Pase, their potential for selective toxicity against trypanosomes may be diminished. This concern needs to be clarified in future studies. We now recognize that the trypanocidal effects of HETA analogs are not always dependent upon their initial phosphorolytic cleavage by Tryp-MTA-Pase. However, we consider the limited ability of mammalian MTA-Pase to cleave HETA to be a common characteristic of HETA analogs, which protects these compounds from metabolism by their host and enhances their bioavailability to bloodstream trypanosomes. Our long-term goal is to develop new HETA analogs with improved in vivo properties compared with those of HETA, a compound which has already been demonstrated to have a broad spectrum of curative effects (summarized in Table 7) . HETT is by far the most potent trypanocide that we have identified in vitro; and further studies with this compound are warranted to determine its biochemical properties, to identify its molecular targets, and to compare its in vivo trypanocidal effects with those of HETA.
